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INFORMED CONSENT: FROM GOOD INTENTIONS TO SOUND PRACTICES
INTRODUCTION
This report is a summary of presentations and discussions at a seminar entitled “Informed
Consent: From Good Intentions to Sound Practices.” This two-day seminar brought together 65
individuals from nine countries on 24–25 May 2001 to discuss challenges of informed consent in
research. (See appendixes for the seminar agenda and a list of the participants.) The seventh in a
series of seminars held every two years, this meeting was sponsored by the Population Council’s
Robert H. Ebert Program on Critical Issues in Reproductive Health. Topics of past seminars have
included abortion research; sexually transmitted infections (STIs) in field programs; and the
interaction of rights, technologies, and services.
The underlying premise of this seminar was that even when those who sponsor and conduct
research start with good intentions, they may have difficulty translating them into practice. The
goal of the meeting was to put informed consent into historical and contemporary perspective
and to explore ways that the barriers to effective implementation can be overcome. This report is
based entirely on the content of the speakers’ presentations and the lively discussions that
ensued.
A BRIEF HISTORY OF INFORMED CONSENT
The idea of informed consent sounds straightforward because the term has become so wellknown to those concerned about ethics in medical research. The familiarity of the term, however,
belies the elusiveness of the concept and the difficulty of its implementation. An explanation for
why implementing informed consent is so challenging may be embedded in the term itself: one
of its components—information—comes from one source (researcher/provider) and the other—
consent—comes from another (participant/patient). This “dyadic relationship” is difficult to
predict and control and, as in any relationship requiring communication, leaves much room for
misunderstanding.
The emphasis placed on informed consent in medical practice and in research is relatively new,
having emerged in the last half of the twentieth century. Its origins are rooted in a history of
abuse. Indeed, it was reaction to past abuses that prompted the codification of ethical principles
for the conduct of research on human subjects in recent decades.
Historians differ on how much informed consent was exercised in medical practice in the
nineteenth century and before. Some suggest that physicians showed little regard for patients’
views or rights. Others argue that physicians in earlier medical traditions did exhibit respect for
patients’ knowledge and autonomy. On closer examination of the evidence, however, it appears
that even those providers who offered their patients information and sought their consent did so
because they believed it would confer some therapeutic benefit, not because they saw it as the
patient’s right. Only in the last several decades has informed consent become central to medical
practice in the United States and Europe, reflecting a growing commitment in broader society to
the right to autonomy and to the rights of the vulnerable.

1

Informed consent in research has its own unique history, going back to the 1930s in the United
States, when courts upheld the importance of knowledgeable consent in medical research. It was
the outrage at the cruelty of Nazi experimentation with human subjects, however, that led to the
creation of ethical codes for research, including informed consent.1 The first principle of the
Nuremberg Code asserts that voluntary, competent, informed, and comprehending consent is
“absolutely essential” in research.2 This monumental step was nonetheless limited in its
application as a practical guide to research ethics.
Despite the outcry against Nazi experimentation, abuse in medical research continued. A 1962
review of state laws in the United States revealed that not a single state had a statute that required
doctors to inform patients receiving experimental drugs of their right to informed consent.3 In
1966, Henry Beecher, a leading thinker in the field of research ethics, published an article in the
New England Journal of Medicine citing 22 cases of unethical practices in research.4 These
included a study in which live cancer cells were injected into patients with dementia without
their knowledge or consent at the Jewish Chronic Disease Hospital in Brooklyn, New York.
In the 1960s, further efforts were made to clarify and codify the concept of informed consent. In
1964, the World Medical Association issued the Declaration of Helsinki, which asserted the
requirement of informed consent for all non-therapeutic research (i.e., research for purposes of
investigation).5 In contrast, in the case of therapeutic research or research conducted by a clinician
investigating possible benefits of a treatment for a sick patient, the declaration said that consent
should be sought “consistent with patient psychology”—to be determined by the physician.
In 1966, in reaction to the Jewish Chronic Disease Hospital scandal, the U.S. Food and Drug
Administration (FDA) issued clear requirements for informed consent in research.6 In the same
year, the U.S. Surgeon General created a policy that required anyone who received funds for
research involving human subjects from the Public Health Service to submit their research for
institutional review, with specific attention to informed consent.7
Yet abuse continued. In 1972, the world of medical research was stunned by revelation of the
Tuskegee syphilis experiment. For some 40 years, researchers had been following the
progression of syphilis in several hundred African-American men. They had withheld treatment
1

2

3
4
5

6
7

Ironically, the United States had itself conducted medical research with human subjects without such consent
during World War II, using the exigencies of war to justify experimentation with psychiatric hospital patients in
the search for a dysentery vaccine and for anti-malaria drugs.
Alemania. 1951. Trials of War Criminals Before the Nuernberg Military Tribunals Under Control Council Law
no. 10, Nuernberg, October 1946, April 1949, vol. 2, pp. 181–182. Washington, D.C.: U.S. Government Printing
Office.
Bayer, Ronald. “Informed consent: Lessons of the past, a guide to the future?” seminar presentation.
Beecher, Henry K. 1966. “Ethical and clinical research,” The New England Journal of Medicine 274(24):1354–
1360.
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human
Subjects, adopted by the 18th World Medical Association (WMA) General Assembly, Helsinki, Finland, June
1964; amended most recently by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000.
U.S. Food and Drug Administration. 1966. “Consent for use of investigational drugs on humans: Statement of
policy,” Part 130: New Drugs. Federal Register 31 (August 30).
U.S. Public Health Service, Division of Research Grants. 1966. “Clinical investigations using human subjects,”
statement of policy, Policy and Procedures Order no. 129.
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from these men, even after penicillin was proven effective to treat syphilis in the late 1940s. By
the time the study was exposed, many of the men had died of the disease or related problems,
their partners had been infected, and several of their children had been born with the disease. A
quarter of a century after Nuremberg, this event shook the foundations of the medical research
community and led to the creation of the National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research. The work of this U.S. federal advisory body
from 1974 to 1978 resulted in the Belmont Report,8 which asserted three principles as central to
research, the first of which is at the heart of informed consent:
Respect for persons—individuals should be treated as autonomous agents, and persons with
diminished autonomy are entitled to protection;
Beneficence—possible benefits should be maximized and possible harms minimized; and
Justice—those who realize the benefits of research should share in its burdens.
The Belmont Report was followed by other commissions, and in 1986 the “Common Rule” was
proposed. Based on an existing 1981 policy of the Department of Health and Human Services
(DHHS), this regulation was extended to all U.S. government agencies. Codified in 1991, the
“Common Rule” finally put into place a comprehensive regulatory framework for human
research in the United States.9
The recent history of informed consent in medical research is one that is dominated by events in
the United States. What relevance does it have for research conducted elsewhere, especially in
developing countries, where cultural, social, economic, and medical conditions may be
extremely different? Some have suggested that the concept of first-person informed consent,
primarily developed in the context of the civil rights struggles in the United States, is not
relevant for much of the developing world and that its application may be an imposition from the
outside, a sort of “ethical imperialism.”10
An analysis of the thinking behind these claims appeared in The New England Journal of
Medicine in 1992.11 The authors, Carel IJsselmuiden and Ruth Faden, identified and analyzed
three common arguments regarding why informed consent is not appropriate or does not apply in
Africa:
It is culturally inappropriate because individuals are not autonomous;
The subjects are not “competent” or the communication difficulties are insurmountable; and
Urgency makes informed consent requirements unreasonable (i.e., informed consent slows
down the search for solutions to urgent health problems).

8

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1978. The
Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. DHEW
publication no. (OS) 78-0012. Washington, D.C.: U.S. Government Printing Office.
9
Department of Health and Human Services, National Institutes of Health, Office for Protection from Research
Risks. 1991. Code of Federal Regulations, Title 45, Public Welfare; Part 46, Protection of Human Subjects.
10
Bayer, op. cit.
11
IJsselmuiden, Carel B. and Ruth R. Faden. 1992. “Research and informed consent in Africa—Another look,” The
New England Journal of Medicine 326(12):830–834.
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The authors found that the first of these arguments—that cultural differences mean that informed
consent is inappropriate in Africa—is based on decades-old anthropological research. Drawing
on studies of traditional societies, this rationale assumes that African culture is homogeneous and
static, and it does not take into account urbanization, education, or the emergence of the modern
nation-state. The authors then dismissed the notion that Africans cannot understand the concept
of informed consent, which essentially equates the cognitive capacity of adults in Africa with
that of children or the mentally ill. While communication across cultures is indeed challenging, it
is hardly impossible. Finally, IJsselmuiden and Faden considered the urgency argument to be
invalid given the slow pace of turning research findings into action in Africa.
Yet the challenge of implementing meaningful informed consent is undeniable. A study by
Quarraisha and Salim Abdool Karim and colleagues, published in the American Journal of
Public Health, evaluated the informed consent process for HIV testing in an antenatal clinic in
South Africa.12 Although consent was sought and women were consistently told that their
participation was voluntary, 84 percent felt that it was “compulsory to participate.” A large
majority said they understood that they were “free to quit the study at any time,” yet they also
believed that the “hospital would not allow them to do so.” And approximately one-third of the
women thought that the care they would receive would be compromised if they quit the study.
The researchers concluded that the consent was informed but not truly voluntary.
After a half-century’s effort to define and realize the concept of informed consent, it is clear that
historical, structural, and practical obstacles remain. Yet the impediments do not justify a
slackening of effort or application. Those committed to the ethical conduct of research continue
to seek ways to overcome these barriers, especially in research conducted with individuals who
are vulnerable because they lack access to resources or services or face the possibility of a lifethreatening disease.
RECENT DEVELOPMENTS AND CURRENT CONTEXT
While informed consent is a critical component of ethical research, it is only one of many
challenging issues in research ethics. Recent trends have highlighted the need to continually
assess the concepts behind and the implementation of research ethics, including informed
consent. Increasingly, and especially in the United States, informed consent has become
extremely legalistic, focused on preventing lawsuits against institutions rather than protecting the
individuals participating in the research or therapy. Driven by a fear of litigation, researchers,
manufacturers, and service providers have created mind-numbingly dense and legalistic forms,
which are hardly conducive to meaningful comprehension and consent. What should be the real
intent—aiding subjects in making informed decisions—is lost in a barrage of detailed
information. Not surprisingly, many potential participants pay little attention to these forms,
because they assume the purpose of the forms is to protect the institution. This has led some
researchers and their institutions to review and revise the forms they use and to begin to question
how they can support and assess comprehension. Internationally, informed consent has been
affected by broader ethical debates spurred largely by the HIV/AIDS epidemic.
12

Abdool Karim, Quarraisha, Salim S. Abdool Karim, Hoosen M. Coovadia, and Mervyn Susser. 1998. “Informed
consent for HIV testing in a South African hospital: Is it truly informed and truly voluntary?” American Journal of
Public Health 88(4):637–640.
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Current Controversies in International Guidelines Concerning Research Ethics
Many people believe that the Declaration of Helsinki, originally promulgated in 1964, has lost
much of its relevance. One of its flaws is that it creates an illogical distinction between
therapeutic and non-therapeutic research.
Article II.6 governs therapeutic research, stating:
The doctor can combine medical research with professional care . . . only to the
extent that . . . research is justified by its potential . . . therapeutic value for the
patient.
Article III.2 mandates that research subjects be volunteers who are either:
. . . healthy persons or patients for whom the experimental design is not related to
[their] illness.
These two articles, strictly applied, would prohibit research on the pathogenesis or epidemiology
of a disease in a study population that has that disease. The research would have to be done with
participants who are healthy or those who have an unrelated condition—an absurd notion in
practical terms.
Another flaw in the Declaration of Helsinki is that it is increasingly out of touch with current
ethical thinking on placebo trials, which has profound implications for research in developing
countries. Article II.3 of the 1996 version of the declaration states:
. . . every patient—including those of a control group, if any—should be assured
of the best proven . . . therapeutic method. This does not exclude . . . placebo
where no proven method exists.
In other words, all participants in research should be given the best-known therapy. This article
creates significant barriers to developing new therapies for conditions for which there are already
“proven” therapies, even when there is virtually no risk from withholding the “best proven
therapy” (e.g., analgesics). It also prohibits research designed to develop relatively less costly
alternatives to expensive therapies, for example, the trials for “short-course” zidovudine (AZT),
described in Box 1.
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Box 1: A Raging Debate—AZT Trials to Reduce Mother-to-Child Transmission of HIV
In the late 1990s, the debate around the ethics of trials in developing countries escalated, provoked by
the controversial testing of AZT13 to reduce mother-to-child transmission of HIV. A few years earlier,
trials in developed countries showed that a regimen of AZT administered to pregnant women before,
during, and immediately following birth cut vertical transmission by 60 percent. Because this proven
regimen, called 076, was expensive and therefore difficult to implement in many developing countries,
some researchers undertook placebo-controlled trials of a much cheaper “short course” of AZT.
These trials led to one of the most acrimonious debates that the medical research community had
experienced in decades.14-20 On one side of the debate were the “principlists” who thought
that it was unethical to administer a placebo when a proven method was available. They felt that these
trials exploited women in developing countries and employed a standard that would never be acceptable
in developed countries. On the other side were the “pragmatists” who felt the trials were justified
because 076 could not be used in many developing-country settings because of its expense (the drugs
alone cost about $800 per woman in 1997)21 and because it required that the health system have the
capacity to administer intravenous AZT during labor and delivery and to provide systematic and early
antenatal care. Many felt that the desperate and immediate need for therapies that could be used on a
widespread basis in poorer countries justified the trials.

A new ethical standard for the conduct of international research has emerged, suggesting that the
standard of care in a trial should be the “highest attainable and sustainable” in that setting.22
“Highest attainable” means that researchers must provide the best care possible. At the same
time, the sustainability stipulation means that researchers must consider the potential for services
to be maintained and for any resulting product to be made available after the trial ends. This
standard attempts to ensure responsiveness to the health needs and priorities of the host country
and to address the issue of access to the product or procedure for trial participants and the
broader community after the trial ends.
Determining the appropriate standard of care within a trial is one of the most difficult challenges
that researchers face, especially in international trials. The provision of free medical services can
be construed as an undue inducement to the host country and to trial participants who would
13

Zidovudine, formerly called azidothymidine, is a drug that slows replication of some retroviruses, including HIV.
Angell, Marcia. 1997. “The ethics of clinical research in the Third World,” The New England Journal of Medicine
337(12):847–849.
15
Varmus, Harold and David Satcher. 1997. “Ethical complexities of conducting research in developing countries,”
The New England Journal of Medicine 337(14):1003–1007.
16
Angell, Marcia. 1997. “Tuskegee revisited,” Wall Street Journal, 28 October.
17
Bayer, Ronald. 1998. “The debate over maternal–fetal HIV transmission prevention trials in Africa, Asia, and the
Caribbean: Racist exploitation or exploitation of racism?” American Journal of Public Health 88(4):567–570.
18
Laurence, Jeffrey. 1997. “Ethical concerns in international HIV trials,” The AIDS Reader 7(5):147–148, 154.
19
Levine, Robert J. 1986. Ethics of Regulation of Clinical Research, ed. 2. Baltimore, Md.: Urban &
Schwarzenberg.
20
Lurie, Peter and Sidney M. Wolfe. 1997. “Unethical trials of interventions to reduce perinatal transmission of the
human immunodeficiency virus in developing countries,” The New England Journal of Medicine 337(12):853–
855.
21
In that same year, many sub-Saharan African countries spent roughly $10 per capita on health annually, meaning
that they would need to spend 80 times their per capita health budget to reduce mother-to-child transmission by
some 60 percent, the rate shown in developed-country trials.
22
Levine, Robert J. “Special populations,” seminar presentation.
14
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otherwise not have access to these services. Trial organizers should consult openly with host
governments and local communities to determine the appropriate standard. They should also
make every effort to ensure that the services set up for the trial are indeed sustainable and that
products that result from the testing process will be available after the trial concludes.
HIV/AIDS Shifts the Debate
In the past, concern about abuse has shaped attention to ethical issues in research, especially
informed consent. Today, it is a sense of urgency that drives developments in research ethics.
The global HIV/AIDS crisis has caused a fundamental shift of focus in this area, from protection
from abuse to access to the benefits of research. In the face of a life-threatening disease, “the
right to be a research subject has displaced the right not to be” and the statement “research is
treatment too” has become a rallying cry.23
This sense of urgency has led activists, especially in developed countries, to challenge the gold
standard of the placebo-controlled trial and to question the role of medical “experts.” The result
of these changes has been a “democratic leveling” of research; human beings are not seen as
subjects of research, but as participants in research.24 Activists have called for access to the
potential benefits of participating in research, including access to potential new and possibly lifesaving drugs and treatments. While this shift has occurred mainly in the United States and
Europe, it has major implications in a variety of other settings and situations.
Globally, the enormity of the HIV/AIDS epidemic, especially in Africa, has altered the
discussion of research on human subjects in other ways. The crisis has highlighted the question
of how global inequality should affect the ethics of international research. For example, how do
standards for ethical research that have been largely generated in wealthy, industrialized nations
apply to nations characterized by poverty and tremendous need? Do ethical standards applied in
diverse contexts produce different conclusions about what is and is not acceptable?
In the late 1990s, the debate around the ethics of trials in developing countries escalated,
provoked by the controversial testing of short-course AZT to reduce mother-to-child
transmission of HIV. The acrimonious debate that ensued—the most public controversy about
research ethics in more than 30 years—pitted “principlists” against “pragmatists”25 and led to
further reconsideration of ethical standards for research—a process that continues today.

23

Bayer, op. cit.
Bayer, op. cit.
25
Caplan, Arthur L. “Informed consent: Miss or bust?” seminar presentation.
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DEFINING INFORMED CONSENT
The goal of the informed consent process should be to increase potential participants’
understanding of the study in order to better enable them to decide whether or not to enroll.
Meeting participants defined informed consent in different ways:
An autonomous action by an individual that authorizes a professional to involve the
individual in research.
[A means] to assure that each individual who participates in biomedical or
behavioral research does so willingly and with adequate understanding of the study
in which he or she freely agrees to participate.
How you make the principle of “respect for persons” happen [in research].
A doctrine of informed decisionmaking that leads to informed consent or informed
refusal.
The Elements of Informed Consent: Information, Comprehension, and Choice
Informed consent is often described as consisting of three components:
Disclosure of information;
Comprehension of that information; and
Voluntary choice.
The Complexity of Disclosure: “Information Overload”
Disclosure of information is the most fully elaborated of the three components of informed
consent. (See Box 2 for the categories of information that should be included in the informed
consent document.) Indeed, the informed consent process as currently carried out often places
too much emphasis on the written document. Long, detailed consent documents can be
overwhelming, confusing, or intimidating for potential participants. A glut of complicated
information rarely facilitates comprehension or informed decisionmaking.
To a large extent, this overemphasis on information disclosure can be explained by a fear of
liability, especially in the United States. In addition, disclosure seems to be the easiest aspect of
the informed consent process for researchers, their institutions, and Institutional Review Boards
(IRBs) to understand and to address. Deciding how much information to present and how to
present it, while complex, is within the researchers’ control. Knowing how to foster
understanding of that information, how to evaluate whether the information has been
comprehended, or how to support a voluntary decisionmaking process is much more challenging.
At the same time, the disclosure component of informed consent has become increasingly
complex, as the list of elements to be disclosed has grown. The requirement to disclose any
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Box 2: Elements of Informed Consent Disclosure
The essential elements of informed consent disclosure are:
The purposes or aims of the study
Study procedures or interventions
Reasonably expected benefits to the subject, the community or society, and/or scientific
knowledge
Risks, discomforts, and inconveniences
Confidentiality of research records and information about individual subjects
Right to refuse to participate and right to withdraw at any time without prejudice
Additional elements of informed consent disclosure include:
Expected duration of the study
Alternatives to study participation (i.e., treatment[s] available)
Treatment and/or compensation that will be provided in the event of study-related injury
The researcher’s responsibility, if any, to provide medical care
Name of person to contact regarding ethical concerns or study-related injury
Conditions under which the investigator may ask the subject to leave the study
Potential conflicts of interest
Whether/how biological specimens will be stored
Whether commercial products will be developed from stored specimens
How study results will be published/communicated to subjects
Whether/how an intervention demonstrated to be effective will be made available after the study

potential conflicts of interest has been added to the recently revised Declaration of Helsinki26 and
to the latest draft guidelines of the Council for International Organizations of Medical Sciences
27
(CIOMS). In the United States, this has become the latest “hot-button” issue, provoked by a
case in Seattle in which investigators conducted research on products of a biotechnology
company in which they had significant financial interest. The patients in the trial were not fully
informed about the existence of reasonably effective standard therapies for their disease, nor
were they told about the researchers’ financial stake in the company, thus highlighting increasing
concern in the United States about informed consent and conflict of interest.28
Another contentious issue related to informed consent relates to the storage of biological
specimens gathered during research and their potential commercial use later. In a study at the
University of California, for example, a spleen removed from an individual was later used to
develop a cell line that was highly profitable. In a controversial ruling, a court decided that the
patient had signed away his right to his biological specimens and their use when he signed the
consent form.29

26

World Medical Association Declaration of Helsinki, op. cit.
Council for International Organizations of Medical Sciences (CIOMS). 1991. International Guidelines for Ethical
Review of Epidemiological Studies. Geneva: CIOMS.
28
Wilson, Duff and David Heath. 2001. “Uninformed consent: What patients at ‘The Hutch’ weren’t told about the
experiments in which they died,” http://seattletimes.nwsource.com/uninformed_consent/, accessed 30 May 2002.
29
Moore v. Regents of the University of California, 51 Cal. 3d 479, 120 Cal. Rptr 146 (1990).
27

9

Despite the fact that much of the attention concerning disclosure is on risk, information is often
presented in a way that does not address the magnitude and likelihood of particular risks in ways
that prospective participants can understand (see “Understanding Risk,” page 14). Disclosure
must address not only physical risks, but also psychosocial risks (e.g., the potential for
discrimination or mental anguish). Findings from research on genetics may affect entire ethnic
groups or communities; for example, information about genetic predisposition to certain
conditions or behaviors may lead to stereotyping. The principle of “respect for communities” has
led some to suggest the controversial idea of community consent for some types of research. But
this raises a set of tough questions about who defines a community and who speaks for it.
Finally, benefits of the research also must be presented in a more useful way, including
information about the probability of each potential benefit and whether it is a direct or indirect
benefit to the research participant or an “aspirational” benefit—to society, to medicine, or to
future patients.
Informed Consent as a Process
Recognizing the limitations of information disclosure alone in facilitating truly informed
consent, greater attention needs to be given to comprehension and decisionmaking. Research
could help to determine the variables that affect understanding (e.g., time of day, language used,
setting in which information is provided, state of mind of the potential participant) and
decisionmaking (e.g., who influences the decision to consent, what matters most to the
participants). Even if potential participants “understand” a particular research study, they may
not fully grasp the implications of it for them. To aid in comprehension, information should be
presented in a meaningful and culturally appropriate way.
Some experts in the field suggest that the informed consent process should be individualized,
letting each potential participant determine what information he or she needs to make a decision.
For example, a short consent form could be provided, with optional appendixes detailing all of
the pertinent information. It would then be up to the individual to decide what to read in order to
make his or her decision. While doing this would risk eroding some aspects of informed consent,
it would recognize and address the fact that individuals have different information needs and
make decisions in different ways.
Another vexing question concerns who defines and measures “adequate” understanding.
Researchers have an obligation to strive for sufficient comprehension of the information to
enable a potential participant to make an autonomous decision. Yet they should not set the
threshold for understanding so high that it risks violating the principle of justice by denying
participation to some people and not others. Who decides what is sufficient comprehension for
an individual to make an informed choice? Should participation be denied to a person who does
not seem to understand all of the information, yet expresses a strong desire to participate in the
study? Is it not paternalistic for a researcher to decide that a potential participant does not
understand the information well enough to decide whether or not her or she will participate in a
trial? While there are no simple answers to these questions, most are clearly contextual: the
higher the potential risks or costs of participation, the higher the threshold for comprehension
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should be. Given the experimental nature of research, informed consent for participation in
research should require a more rigorous measure of understanding than for therapy.
Decisionmaking, like comprehension, is poorly understood and has been inadequately studied.
Striving to provide information in an understandable way to support decisionmaking, as
described above, is primarily the researcher’s responsibility. The researcher should be alert to
coercive influences that interfere with autonomous decisionmaking. It is generally agreed that
neither community nor partner consent should be required for an individual to participate in
research, although the community should be brought into the process and consulted, often as a
preliminary step (see “Consenting Partners,” page 26). Researchers should guard against
providing excessive incentives for participation and make it clear to potential participants that
they will not be denied regular services if they decide not to join a study.
The Informed Consent Process: The Role of Institutional Review Boards
An important part of the informed consent process is the IRB. The IRB is the “institutional
conscience” that is expected to safeguard the rights and well-being of human subjects in
research. In the United States, the Common Rule requires IRB review of study protocols,
including the informed consent document. If more than one institution is involved in a particular
research project, each will require review by its own IRB. In the case of international research,
reviews are done in the host country/countries and the sponsoring country. The differences in
interpretation and priorities that emerge in IRB reviews within and between cultures underscore
the fact that IRB review is a subjective process. While such differences in perspective can lead to
confusion and conflict, they can also generate important discussion and debate on putting ethical
principles into practice in the treatment of human subjects.
Given the complexity of IRB review across institutions and countries, international multi-center
studies can benefit from the establishment of a central coordinating group. This group, or the
lead IRB, can identify those elements of a trial that are “core”—that is, that require consistency
in the informed consent form and process across sites—and where there is room for local
variation. The central coordinating group or IRB can also resolve any important disagreements
among IRBs. It is to be expected, however, that forms and processes will vary somewhat,
reflecting local realities; indeed, IRBs have an obligation to change an informed consent form or
process when local conditions dictate it.
IRBs face several constraints in their review process. The dearth of research on elements
essential to informed consent comprehension and retention means that generally there is little
information on optimal forms or processes upon which IRB members can draw in their
deliberations. They may lack knowledge and information about the study population or research
context and may be inconsistent or subjective in their views. IRBs are often expected to provide
an ethical review of protocols that some members may not have the technical expertise to
accurately judge. They may also be asked to review studies in which the quality or relevance of
the science is weak. IRB members often find they must identify a balance among protecting
individuals, exercising professional restraint, and allowing scientific progress to go forward.
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Perhaps the most significant limitation of IRBs with respect to informed consent is that IRBs
review and approve research protocols (including informed consent forms), but they do not play
an active role in monitoring studies. IRBs do not conduct site visits, nor do they monitor the
informed consent process on an ongoing basis. They do not witness how consent is obtained,
review or approve the researchers’ strategies for educating and informing potential study
participants, or examine who is involved in the informed consent process (e.g., the researcher or
an independent third party). Their focus is the review and approval of the informed consent form
and any other study materials written for participants, which reinforces the tendency to view
informed consent as written documents rather than an ongoing process.
Given that monitoring is beyond the purview of IRBs, other mechanisms could be established to
ensure that every effort is made to inform potential study participants about the risks, benefits,
and procedures involved in a study. These could include building more attention to the informed
consent process into ongoing study monitoring or establishing independent monitoring by
community advisory boards.
As currently conceived, IRBs are closed bodies that could benefit from increased transparency,
especially at the local level. Ideally, IRBs would include representatives of study populations. As
this is not always feasible, the interests and perspectives of study participants should be
incorporated into the design and review of the research in other ways. Examples include
community advisory boards, social science research in the study population, and community
consultations.
A recent trend is to strengthen the capacity of IRBs through training of members (and
researchers) to enhance their ability to focus on substantive issues in the informed consent
process, rather than simply conduct a one-time paper review. Indeed, some effort is being made
to develop an IRB certification process in the United States. Investing in training of IRB
members and researchers should not be just another bureaucratic requirement, but rather should
help to ingrain research ethics, including a commitment to informed consent, as integral to the
research process.
As mentioned previously, while IRBs play a critical role in reviewing protocols, including
informed consent materials, they are not charged with overseeing or monitoring research. IRB
review is a critical component of conducting ethical research, but it does not in and of itself
ensure that a study will be conducted in compliance with the highest ethical standards. Therefore,
the ultimate responsibility for ensuring that ethical principles are adhered to lies with the
researchers designing and conducting the study.
IMPLEMENTING INFORMED CONSENT
One of the principal challenges of implementing informed consent is to present information to
potential study participants in ways that aid their understanding and support their
decisionmaking. Practical efforts to improve the informed consent process have resulted in novel
approaches to conveying information.
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Efforts to Strengthen the Informed Consent Process
Improving the Informed Consent Document: The NCI Working Group
In the late 1990s, staff at the National Cancer Institute (NCI) of the United States became
concerned about the state of informed consent in cancer treatment trials. They believed that
informed consent had become a liability management tool for institutions and that the goal of
providing information to help people make a decision had been lost. The informed consent
documents were long, difficult, and complex. To address these concerns, NCI staff established a
working group to review the informed consent process in cancer treatment trials.30
The working group—which consisted of 35 people, including patients, investigators, lawyers,
and communications experts—worked together for two years. Members of the group reviewed
the requirements under the Common Rule (see page 3) and drafted recommendations for the
informed consent process, which included the following comments on the required elements of
information disclosure:
The description of the purpose of the study should include a statement on the limitations of
potential benefits for the participant.
The research regimen should be clearly distinguished from the existing standard of care, so
that potential participants understand what is different about the research.
Possible benefits should not be overstated.
Possible side effects should be listed as a whole, not grouped by specific drug or procedure,
and they should be categorized by probability and severity.
Risks associated with usual medical care should not be included.
Patients, both women and men, should be informed of reproductive risks.
Patients should be informed of possible non-physical risks.
With the permission of researchers, the NCI working group rewrote informed consent documents
for existing studies. The new forms were reviewed and critiqued in focus groups, after which
further revisions were made. The final product, a two-page form with addendums, was used by
the working group to develop a template.31 The revised informed consent form:
Uses the second person and is conversational in style;
Employs a question-and-answer format; and
Uses schemas or visual representations of the text.
Currently, other parts of the National Institutes of Health (NIH) are adopting similar forms, and
some of the same revisions are being made in the United Kingdom and Germany. In addition, the
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NIH is funding studies on research ethics, including informed consent. The NCI is also
experimenting with the use of alternative means of conveying information (e.g., videos and
pictures). It has found that using these tools results in only a small improvement in comprehension.
Not surprisingly, the interaction between the health professional and the patient or participant often
makes the most difference in the effectiveness of the informed consent process.
Finding Ways to Aid Understanding: The Flower Diagram
Researchers conducting a community development project among commercial sex workers in a
Vietnamese community in Cambodia developed an innovative technique to improve the
information disclosure process. Women in the community development project were young and
had little money or education. Often they had been brought to Cambodia by relatives or
“middlemen” who may have deceived them about the nature of the work in which they were
engaged. Many of the women arrived in Cambodia already in debt and were forced to give 50
percent of their profits to brothel owners, in addition to paying for water, electricity, clothing,
laundry, and police bribes and sending money to relatives at home. They faced harsh working
conditions and suffered violence at the hands of clients and the police.
Many of the women in the project could read or write, but even those who were literate found the
informed consent form boring and difficult to understand. Researchers responded by
incorporating a visual image and exercise into the informed consent process to communicate to
the women the risks and benefits of participation in the project and to stimulate their thinking
about the implications of the project for their lives. First, researchers divided the women into
three groups of eight to ten women. Using the image of a flower, the women were asked to create
petals to represent the benefits of participation and thorns to represent the risks. The three groups
then reunited and combined their petals and thorns into one flower (see Figure 1).
The researchers concluded that the flower exercise engaged the women’s interest and aided their
understanding. It was also an easier and quicker way to present relevant information. While this
exercise has not been formally evaluated, it provides an example of adapting the informed
consent process to different populations and local conditions.
Understanding Risk
A significant part of the informed consent process is communicating and understanding the risks
involved in participation in a study. The field of risk analysis offers some interesting and useful
information about risk and the ways that people assess risk and apply risk assessment to their
own lives.
People face many kinds of risk—financial and health risks, risks of natural disasters, and so
forth. Risks to health occur at both the population and individual level. In assessing risk, three
questions should be asked:
What can go wrong?
How likely is it that something will go wrong?
If something goes wrong, what are the consequences?

14

Figure 1: The Flower Diagram32

Petals
• Learn more about women in other brothels.
• Get new information.
• You will learn more about us and life in Svay Pak.
• We will learn more about you.
• We can come here to “ease our mind” and talk
to someone.
• Make new friends, have fun.

Thorns
• During the time spent participating, the
opportunity to be with clients would be lost.
• Loss of leisure time usually spent napping, relaxing,
socializing.
• Some (other) brothel managers might not be happy with
sex workers who miss time with clients.
• Talking about some topics in front of other women can be
dangerous. If managers or other sex workers heard some
of the information that was supposed to be confidential, it
could be damaging.

The informed consent process often focuses on the first of these questions—what can go wrong.
For the purpose of avoiding liability, all the things that could possibly go wrong are listed. Less
attention is given to weighing the probability of something happening or to evaluating the
consequences for the individual.
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The way that risk is presented and framed has a major effect on how it is understood and
interpreted. Some of the factors that affect understanding are: quantitative or qualitative
presentation, the numbers used (e.g., 2 in 10, 1 in 5, two-tenths, 20 percent, and so forth), and
description of absolute versus relative risk. Not surprisingly, who delivers the information is
important and influences comprehension and interpretation.
The field of risk assessment offers some interesting lessons about how people understand risk in
the face of limited information:
Generally, people exhibit an “optimism bias”; they feel “it won’t happen to me.” For
example, one researcher asked a random sample of adults to rank their risk as belowaverage or above-average for 32 hazards, including asthma, drug addiction, food poisoning,
and lung cancer. The study found a “significant optimism bias” for 25 of the 32 hazards.33
People use “cognitive heuristics to make judgments about uncertain events.”34 One of these
is “availability,” or the ease with which an event can be imagined or recalled. Incidents that
are widely reported in the media are perceived as more likely to occur than those that are
not, making dramatic, “newsworthy” events seem disproportionately risky. The result is
that rarer risks (e.g., airplane crashes) are overestimated and more common risks (e.g.,
traffic accidents) are underestimated. The Internet also influences risk perception, because
information on the World Wide Web may seem authoritative, even if it is not. Immediacy
and proximity of an incident also influence perception of risk. For example, seeing a
burning house may increase the perceived risk of a fire in comparison to hearing about a
fire on the radio. And, the more recent the experience, the more “available” it is and the
more likely it will be viewed as a risk.
Another factor is the “anchor,” or starting point: the information people hear first
influences their assessment. For example, on average, when asked to quickly estimate the
product of 1×2×3×4×5×6×7×8, people will come up with a smaller number than if asked to
estimate the product of 8×7×6×5×4×3×2×1. Unrelated information provided
simultaneously may also change perception. For example, two groups of people were asked
to estimate to themselves the percentage of countries in the United Nations that are in
Africa. A roulette-type wheel was then spun in the background; participants believed it
would stop on a random number between 0 and 100, but in fact it was fixed to stop either
on 10 or 65. After the wheel was spun, people were asked whether their estimate was
below or above the number showing on the wheel, and then they were asked to reveal their
actual estimate. The group that saw 10 on the wheel gave an average of 25 percent as the
percentage of African countries in the United Nations, while the group that saw 65 gave an
average of 45 percent.35
The way that a risk is framed also influences people’s assessment of it. For example, using
the terms “lives lost” or “lives saved” may impart a negative or positive association and
influence the perception of risk.36
33

Weinstein, Neil D. 1987. “Unrealistic optimism about susceptibility to health problems: Conclusions from a
community-wide sample,” Journal of Behavioral Medicine 10(5):481–500.
34
Thompson, Kimberly. “What is it?: Understanding and communicating risk,” seminar presentation.
35
Ibid.
36
Ibid.
16

Visual aids have been shown to be helpful in communicating risk and probability and to
overcoming people’s inability to understand numbers and even words. For example, “risk
ladders” can help to convey where a risk falls in relation to other hazards. Showing people 100
dots on a piece of paper and indicating that a certain event would happen to two of those dots can
effectively convey probability.37
In risk assessment, “perception equals reality,” because people act on what they believe to be
true, regardless of the facts. Hence the way that information about risks (and benefits) is
provided greatly influences people’s perception of risk and the decisions they make. More
research about risk assessment is needed, especially on variability and uncertainty. Variability is
the difference in real risk between individuals (e.g., how the use of air bags affects children
differently than adults). Uncertainty is the lack of perfect knowledge about risk. Often little is
known about research risks, especially in Phase 1 clinical trials. Nonetheless, it is important to
talk through these uncertainties with potential participants and to communicate the possibilities
of risk to them.
EVALUATING INFORMED CONSENT
Although informed consent is a part of virtually all research protocols, surprisingly little research
exists on it. Evaluating informed consent presents a number of challenges. It is important to
decide which aspects of informed consent are to be assessed: Is the goal to assess what the
researcher or clinician told the participant, what that participant can remember, or what he or she
actually understood? Interpretation of results also can be difficult. For example, if a participant
says that she was not given a piece of information, was the information not provided, provided
but not understood, or understood initially but now forgotten or confused? If the information was
not understood, the reasons may vary: Too much information was given, it was not presented
well, it was too technical, or it was perceived as having been given in order to protect the
researcher. It may be that the person was given information, but did not want to know it. Even if
a participant can recall information provided, it may not have been understood.
The methodology for studying informed consent also presents challenges. Researchers can
review informed consent documents, listen to audiotapes of conversations, or question
participants after the fact. Evaluating informed consent with people outside of a given trial is an
alternative, but this has limitations, too: The emotions of the participants in an informed consent
study are not likely to be the same as those of people who are truly considering participation in a
trial. Finally, careful phrasing of evaluation questions is important so that the results of an
informed consent assessment accurately reflect the understanding of participants.
A review of some of the existing research on informed consent and two examples of assessments
that have been conducted provide some interesting lessons for those seeking to improve
implementation and evaluation of the informed consent process.
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Review of Existing Research on Informed Consent
A review of research evaluating informed consent found four studies that assessed informed
consent in research, ten studies that evaluated informed consent in clinical procedures, and 12
that focused on informed consent techniques.38 Some of the findings of this research include:
Most study participants think that they understand the information provided better than
they actually do.
The timing of both disclosing information and seeking consent matters. A few of the
studies on informed consent found that it is better to provide participants with written
information in advance and then go through the document orally at the time of the
procedure. Other studies found that most people do not read such information.
Possible side effects of treatments are remembered more easily than the burden of
participation in research (e.g., the number and frequency of visits, tests, and so forth).
In research, healthy people seem to understand the study better than those who are ill.
Participants in cancer trials, for example, are often confused about the distinction between
therapy and research. In general, the older or sicker the person, the less well he or she is
likely to understand.
People are less likely to remember “bad news,” for example, a study of the informed
consent process for a detached retina operation found that many participants did not
remember being told that they might go blind.
The more a participant understands about a study, the more likely he or she is to comply
with the study requirements.
Informed consent in reproductive and sexual health research may differ from informed consent
in medical treatment, because trial participants are usually healthy and thus have a broader range
of genuine choices. Researchers at Family Health International conducted a study of the
informed consent process and the understanding of risk in a contraceptive clinical trial in four
sites.39 At three of those sites, in Latin America and the United States, written forms were used
and at the fourth, in Africa, they were not. The researchers found that:
Participants without written materials recalled information as well as those who had
received the information in writing.
Altruism—the desire to help others—was given as an important motivation for
participation.
Recall was good, even when understanding was limited. For example, participants
remembered the numerical assessments of pregnancy risk, but still thought that the risk of
pregnancy was lower with a spermicide than with the pill or IUD.
The longer the participants were in a study, the better they understood that they could leave
it if they wished.
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What should be done if it is clear that people do not fully understand the information that they
have been given, but nonetheless choose to participate? Who decides what constitutes sufficient
understanding? These questions have no simple answers, but clearly researchers need to ensure
that the most important information is understood. As discussed in “Informed Consent as a
Process” (page 10), the threshold of understanding for participation in research should be higher
than that for treatment. In addition, the standards for comprehension must be related to the
potential risk for participants: The higher the risk, the more rigorous the measure of
comprehension.
Finally, the fact that clinical trials are research is often poorly understood and, indeed, may not
be of importance to the participants. For researchers, answering the research questions is the
focus, but the priority for participants may be the potential benefits to themselves, or, if they are
motivated by a sense of altruism, to others. This creates a dilemma: If answering the research
questions is not the main priority of the participants, how important is it that they comprehend
the details related to them, let alone that they can recall them later? This underscores the point
that participants may want and need different kinds of information in order to make their
decisions (see “The Elements of Informed Consent,” page 8).
Case Studies of Evaluation of Informed Consent
A Microbicide Safety and Acceptability Trial in South Africa
The Population Council is conducting clinical trials of its candidate microbicide Carraguard™, a
product that potentially could be used topically to reduce infection from HIV/AIDS and other
sexually transmitted infections. In an effort to ensure truly informed consent and voluntary
participation in communities of people at high risk of HIV infection, the researchers assessed the
informed consent process at several points before, during, and after a Phase 2 expanded safety
trial of Carraguard in South Africa.
The design was a randomized, placebo-controlled, double-blind trial. Participants were instructed
to insert Carraguard or its matching placebo vaginally every other day, and to use the gel and a
condom every time they had sex. Monthly follow-up visits included safer sex counseling, a
gynecological examination, and an interview.
Prior to beginning the trial, the informed consent form was pre-tested in the recruitment
communities. The consent form, written at a U.S. eighth-grade reading level, had already been
approved by the local ethical review committees at each of the study sites and by the Population
Council’s IRB. A lexicon was then developed to ensure clarity and consistency in translation,
particularly for words and concepts (such as “placebo,” “randomization,” and “microbicide”)
that do not exist in Xhosa and Tswana, the local languages.
Local social science researchers conducted focus groups and in-depth interviews to assess
women’s understanding of the purpose of the trial and to solicit feedback on the readability and
language used in the form. The results revealed that the women found the information
overwhelming and the layout of the form difficult to follow. They did not fully comprehend the
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research concepts and were confused by the primary and secondary purposes of the study (testing
safety and testing preliminary effectiveness, respectively).
Based on these findings, the informed consent form was rewritten to clarify the main purpose of
the study. The layout was also revised: Shorter sentences were used and lengthy paragraphs were
replaced with bulleted lists. In addition, Population Council staff worked with local study staff to
develop a recruitment script and flipchart to explain the trial to potential participants. Involving
the staff who would do the recruitment and counseling in the process of reviewing and revising
the informed consent materials also served an important training function.
Once the new informed consent form and procedures were implemented, interviews were
conducted with the first 20 women actually enrolled in the Phase 2 trial. Based on the results of
this evaluation, no major changes were made to the form itself. Instead, the researchers focused
on improving the process. A series of questions was developed for use by study staff to probe for
understanding during the consent process. To supplement the informed consent form, researchers
created a booklet with illustrations and analogies to communicate difficult concepts.
The researchers made the following recommendations from the two assessments and their overall
experience:
Standardize the informed consent process for study staff (e.g., by developing scripts or lists
of questions).
Focus on the staff. Select personnel carefully; not everyone will be able to convey complex
information. Provide education and training to increase staff commitment to informed
consent and to give them the tools they need carry it out.
Listen to staff feedback. Ask them to identify areas that participants have difficulty
understanding. Get staff input on how to improve the documents and process.
Use simple terms and find analogies that potential study participants can understand.
Use various approaches to aid understanding that build on each other and work together,
such as flipcharts, question-and-answer formats, visual aids, and analogies.
Perhaps the most important lesson the researchers learned was that developing and assessing a
process for informed consent can be long, complex, and costly, and to do it effectively, resources
and time must be dedicated to the process.
A Reproductive Morbidity Study in The Gambia
In 1981, the Medical Research Council of the United Kingdom conducted a reproductive
morbidity survey in 20 villages in The Gambia. The researchers recruited 1,348 women 15–54
years old for the study, which involved an interview about their general, reproductive, and
mental health; a gynecological examination at the village health post; and the taking of blood and
urine samples.
The informed consent process was conducted at three levels. The researchers first met with
village leaders, including religious leaders and traditional birth attendants, and told them about
the nature and purpose of the study. Once the leaders had agreed, the researchers held meetings
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with village residents to talk about the study. Finally, individuals who were interested in
participating in the study went through a one-on-one informed consent process, after which they
were asked to sign a consent form that had been translated into the three local languages.
Researchers then did a follow-up study of comprehension and acceptability of the original
research project. They were interested in discovering whether informed consent had been
meaningfully sought and granted in a context in which the study participants are poorly educated
and have little access to health care. They also wanted to find out whether the women had
learned anything about reproductive health. The methodology of the follow-up study was semistructured interviews (Box 3 describes some of the findings and provides examples of the
responses).
The researchers found that most of the women had understood that the purpose of the original
study concerned health, without fully comprehending that it was a research project. The
women’s comprehension of the procedures was also limited, and they had a strong tendency to
place their trust in the doctor. Eighty-seven percent of the women said they thought they had
benefited from participating in the study, but many could not define how. Nearly one-third
mentioned treatment as a benefit. The researchers also looked at the people involved in making
the decision to consent to the study and found that two-thirds of the women had consulted
someone.
Were the participants informed? Most had a basic understanding that reproductive health was the
focus of the study, but they did not comprehend well that the study’s purpose was research. Had
they consented? Many had consulted with their husbands, and some felt that they could not
participate without their husbands’ permission. The opinions of others (e.g., mothers-in-law)
were sometimes influential. The community perspective was important, but not determinant. A
major incentive for participating was the availability of better services and treatment, which
raises the question of whether availability of services and treatment served as too strong an
incentive, thereby constituting “undue inducement.”40
The researchers drew the following conclusions from the follow-up study:
Staff play an important role and need to be provided with tools and training.
The informed consent form should be standardized, but staff must have some flexibility.
For example, in this situation, the field workers adapted some of the language to use with
the older women.
Information may need to be simplified and repeated. It may also be helpful to use
alternative means to communicate information (e.g., videos).
Participants should be told clearly what they should expect to hear back from the
researchers about study results.
Providing treatment can improve acceptability and may provide study participants with a
strong incentive to consent to research.
40
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Box 3: An Evaluation of Informed Consent in The Gambia41
Did the women understand the purpose of the study?
They are checking to know whether we have diseases or not.
They came to give free treatment to us all.
The reason is just to take our blood and then go away.
I think they are doctors; that’s why they came . . . because they know better than us.
I was examined but they did not tell us why.
Who gave the consent?
33 percent—mostly older women—had consulted nobody.
I did not discuss with anyone because I want to be healthy.
47 percent had consulted their husbands.
I discussed with my husband and he felt that they wanted to help us.
I did not discuss with my husband because he was not around, and when he came he
said I should not have joined.
What did the women understand about the procedures?
I did not feel anything bad, but sometimes I felt shy.
I did not have any problem with it as the doctor is doing her work.
I did not know why the doctor examined inside my body.
I was not told my results but I was given medicine.
You don’t understand anything about the work.
What did the women gain from the study?
31 percent mentioned the treatment.
I was tested and they found I was infected and I was treated.
9 percent said they had gained knowledge.
People were found infected without any symptoms, this made us surprised and we
gained knowledge.

Final Reflections on Evaluating Informed Consent
While the seminar participants recognized the need to evaluate the informed consent process in
order to find ways to improve it, they also identified several challenges:
The informed consent evaluation may require IRB approval depending on its design. This
could slow down the process of evaluating informed consent procedures.
Independent review of the informed consent process helps to avoid possible conflicts of
interest on the part of the researchers involved in the primary research. Even independent
researchers are not immune to possible conflicts of interest, however, if they are paid by
the sponsors of the original research project. The additional time and expense required for
an independent review may also prolong and complicate the process to the point that it
41
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becomes an undue encumbrance and a significant barrier to doing any evaluation at all. If
measures are taken to avert conflicts of interest, an internal review process can be more
manageable.
Integrating the review of informed consent into the research process creates an important
opportunity to train the field staff and to monitor and adjust the informed consent process
on an ongoing basis.
Monitoring and evaluation should focus on building the capacity of staff to communicate
with participants and on improving implementation of the informed consent process, rather
than enforcing overly rigid procedures.
The need to monitor and evaluate informed consent should be kept in perspective. Not all
research involves the same degree of risk or burden for the participants. The greater the
potential risk or burden, the more essential it is to review and monitor the informed consent
process rigorously.
INFORMED CONSENT IN SPECIAL POPULATIONS
Some study populations may be more vulnerable—due to age, gender, socio-economic status, or
physical, mental, or emotional state—and thus require special consideration in the informed
consent process. When working with people in these groups, researchers should seek ways to
strengthen their autonomy and to support their ability to make informed decisions.
Adolescents: Balancing Autonomy, Protection, and Justice
In conducting research among adolescents, a potential conflict arises between the desire to honor
the emerging autonomy of the individuals and the need to protect them. While adolescents are
often inclined to be motivated by altruism, they are also particularly vulnerable regarding body
image and the need for privacy and confidentiality. Specific guidelines have been developed to
address some of the complexities concerning research with children and adolescents—providing
an illustration of the kind of thinking needed to find practical ways to apply the principles of
informed consent.
Laws regarding children have evolved over time. Under English Common Law, children were
considered property. Over time, the law in the United States has recognized children’s autonomy,
including the right to treatment and the right to privacy, but it was not until 1967 that the U.S.
Supreme Court classified children as persons with the right to due process. Despite this
recognition, children are presumed incompetent, without legal capacity to give consent, and
parents are viewed as the best protectors of a minor’s interests. When a conflict of interest arises
between the child and the parent(s) or guardian(s), however, the state may intervene on the side
of the child.
In the United States, state laws vary. Many acknowledge the right to treatment, a sort of limited
autonomy, for specific “medical conditions,” such as STIs/HIV, pregnancy, and drug use. The
ethical foundation for these laws is not belief in the capacity of adolescents, but rather a
utilitarian view that the denial of such treatment could adversely affect their welfare by
preventing them from seeking services.
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Reflecting the broader debates around the principle of justice and participation in research, the
understanding of the balance between protection from risks and access to benefits for adolescents
has begun to shift. Children and adolescents cannot fully benefit from research unless they are
allowed to participate in it. The lack of research involving young people has resulted in their
exposure to unknown risk; for example, some 70 percent of medicines used in pediatrics have
never been tested on children. A relatively new NIH policy states that “children” must be
included in research, as follows:
. . . children (i.e., individuals under the age of 21) must be included in all human
subjects research conducted or supported by the NIH, unless there are clear and
compelling reasons not to include them.42
The literature on the cognitive development of young people suggests that by the age of 12–13
years, they begin to understand abstract concepts, and that at approximately 14 years, their
cognitive abilities roughly equal those of an adult. The term “assent” was developed to address
the existence of a significant ability to make decisions in the absence of legal capacity. It is
defined as:
. . . a child’s affirmative agreement to participate in research. Mere failure to
object should not, absent affirmative agreement, be construed as assent.43
The assent process should be individualized, based on the ability of the young people involved:
. . . the IRB shall determine that adequate provisions for soliciting the assent of
the children when in the judgment of the IRB the children are capable of
assenting . . . the IRB shall take into account the ages, maturity, and
psychological state of the children involved.44
In addition to the assent of the child, parental “permission” is required.45 Requiring parental
permission, however, may cause some young people to be reluctant to reveal risky behavior or to
seek services. In certain instances, such as child abuse, parental permission may be waived. In
this case, alternative means are established to protect the young person, including:
Court approval;
Designation of a child advocate, who must have no connection to the research;
Permission from a surrogate parent; and/or
Community consultation.

42

National Institutes of Health (NIH). 1998. NIH Policy and Guidelines on the Inclusion of Children as Participants
in Research Involving Human Subjects, Section III: Policy. Bethesda, Md.: NIH.
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U.S. Department of Health and Human Services, Office for Protection from Research Risks, and National
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In the mid-1990s, the Society for Adolescent Medicine developed new guidelines for adolescent
health research, including the question of parental permission. Pointing to evidence of
tremendous variation in IRB decisionmaking concerning research involving young people,
society members believed that research was increasingly being restricted, with negative
consequences for adolescents. They viewed the existing federal guidelines as inadequate and
initiated a national consensus process to develop new ones, attempting to balance respect for
parents as primary protectors of their children with the growing capacity and emerging autonomy
of adolescents.46 Using a typology of risk for health research with children47 in the federal
regulations (see Box 4), the guidelines recommend the following:
In minimal risk situations, parental permission may be waived, as long as privacy
and confidentiality are ensured, the adolescent provides informed consent, the
adolescent is encouraged to consult with an adult prior to participation, and
procedures are established for the adolescent to seek confidential assistance.
For research that is of potential direct benefit to the participants, but of greater than
minimal risk, more should be done to augment the adolescent’s capacity to give
consent and to find an adult who is committed to her or his welfare and willing to
provide support. Furthermore, a professional unconnected to the research should
assess the adolescent’s capacity to give informed consent.
Despite the many barriers to conducting research with adolescents, the concrete guidelines
referred to above can help to ensure the validity of the informed consent process, while enabling
greater inclusion of adolescents in research.

Box 4: Typology of Risk in the Regulations for Research with Children
The range of risk involved in research varies tremendously, from simple survey research, where
the risk is minimal as long as confidentiality is assured, to the administration of pharmaceuticals
that could induce serious side effects or even death. A typology of risk has been developed within
the regulations for research with children, as follows:
1. Minimal risk (e.g., surveys, drawing blood, and so forth) where the potential risk of harm or
discomfort should not exceed that of “daily life,” such as that encountered in a routine visit to
the doctor’s office.
2. Greater than minimal risk, but with direct benefit (e.g., therapeutic trials) where the potential
risk is justified by the potential benefit.
3. Greater than minimal risk with no direct benefit (e.g., non-therapeutic research) where
generalizable knowledge to be gained is of “vital importance.”
4. Research requiring special approval (rarely used).
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Consenting Partners
Under what circumstances, if any, should the partners of study participants be asked for their
consent? In the case of reproductive and sexual health research involving women, such as
contraceptive trials, should men be asked to give their consent? The debate concerning the
appropriateness of seeking male partners’ consent for women’s participation in research revolves
around two issues:
Sensitivity to cultural dynamics in which women are not recognized as autonomous beings
and/or the community plays a key role in decisionmaking; and
How women’s participation in research may affect men, including the social,
psychological, and biological effects.
It is argued that the concept of individual decisionmaking may violate some cultures’ emphasis
on the collective. This view was captured by an editorial in the Journal of the American Medical
Association in 1995 that referred to a body of literature stressing that the individual is embedded
in society and that family and community decisionmaking should be taken more seriously by
researchers. The editorial states, “Autonomous decision making may counter family-centered
values and the social meanings of competency and . . . obedience.”48
Others challenge this view, which they say preserves existing power structures: “By appealing to
a sense of cultural relativity or cultural respect, it is the male value systems that are given
precedence. . . .”49 In a recent article, bioethicist Ruth Macklin refers to unpublished guidelines
of the Scientific and Ethical Review Group of the World Health Organization’s Special
Programme of Research, Development, and Research Training in Human Reproduction that state
that partner agreement “violates the autonomy of research subjects and their right to
confidentiality.”50 Nonetheless, Macklin points out, the guidelines also say that the prohibition
against partner agreement may occasionally be outweighed if denying the eventual benefits of
the research to the entire society would be “so great a drawback”:51
However, because of existing cultural, religious, political or legal constraints it is
sometimes impossible to achieve the ethical ideal and exceptions to this general
principle may have to be accepted. . . . In rare circumstances it may be necessary
for researchers to conform to local custom and request partner agreement.52
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In 2001, the U.S. National Bioethics Advisory Commission released a report on clinical trials in
developing countries, which suggests that in some cases it may be necessary to seek the partner’s
permission, but only as a supplement to—never a substitute for—a trial participant’s consent:
In none of these cases should permission from another person [e.g., husband]
replace the requirement of the individual participant’s [e.g., woman’s] informed
consent.53
The most complex situation is one in which a product under investigation could have a biological
or physical effect on the partner. This has been an issue in the context of microbicides trials. A
report from a 1997 symposium on ethical considerations in the clinical testing of microbicides
recommended that once safety has been established in early trials (e.g., male safety studies),
researchers should not require partner consent.
Not only would [conditioning a woman’s involvement in a clinical trial on the
consent of her male partner] undermine women’s autonomy, but it could put some
women at risk of violence or abandonment. . . . It also raises questions about how
to handle situations where women may have several partners. . . . Once safety
ha[s] been established, trials should no longer require partner consent.54
For example, in the Population Council’s Phase 2 microbicide trial in South Africa, staff offer
information and counseling for men, but it is the woman who decides whether to suggest to her
partner that he make use of these services. In practice, women have often wanted their male
partners to be involved. By encouraging women to make that decision, the researchers have
sought to enhance, not diminish, their autonomy.
For researchers seeking to find the balance between respect for individual autonomy and cultural
sensitivity, the compromise may be to create an informed consent process that enables the
participants to consult and involve others without requiring them to do so. Ideally, such
consultation can contribute to social change, by creating opportunities for learning, for
communication, and for shared responsibility.55
Informed Consent and the Rights of Refugees
Refugees and displaced persons may live in circumstances and share characteristics that make
them especially vulnerable, thus requiring special attention in the informed consent process.
Most refugee situations stem from long-term conflicts, and the countries and people affected are
among the world’s poorest and have limited autonomy. An exploration of the conditions that
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affect informed consent among refugees offers a useful illustration of the factors that researchers
should consider when doing research with any potentially vulnerable population.
Refugees56 have the same rights in research settings as any other persons, although they are not
named specifically in the international guidelines for research, such as those by CIOMS. In 1997,
a WHO committee recommended that research in emergency situations should be of immediate
and direct benefit to the affected population. Furthermore, it stated that the research should be
done in any other, non-emergency setting, if at all possible. Since then, the discussion has
shifted—along the lines that the general debate around the risks and benefits of research has
moved—to emphasize the potential benefits of research to refugees.
Researchers working with individuals in forced migration settings should be guided by the same
standards for informed consent as in any other situation, but they also need to take into account
some factors specific to the population, including:
Refugees often are dependent on others for food and other material needs. Given their
dependency on others for survival, they may not feel that they are in a position to make
choices about participation in research. They may believe that researchers control the
resources and thus say whatever they think researchers want to hear in the informed
consent process. In this situation, ensuring that consent is truly voluntary is a challenge.
People who have been forced to migrate may be traumatized—by war, by physical
violence, by being forced out of their homes—possibly affecting their ability to understand
information and to make decisions regarding informed consent. Researchers must take
special care to consider the participants’ ability to comprehend and to decide freely.
Refugee organizations often function in crisis mode, responding quickly in emergencies,
that may not be consistent with the need for the long-term planning that research requires,
including IRB review and careful implementation of a thorough informed consent process.
Good research that produces sound data can help to design better services for refugees. In doing
that research, however, investigators need to recognize the special ethical and practical
challenges inherent in emergency settings and pay close attention to how those challenges affect
the informed consent process.
COSTS AND BENEFITS
Implementing and assessing informed consent, including providing adequate training for staff
and thorough monitoring of the process, requires resources. Therefore, donors who support
research should expect to designate funds for this purpose. Little is known about the actual costs
of implementing informed consent in research, however, such costs are likely to be a very small
part of the total research budget. Better cost analyses of informed consent could put those costs
into perspective relative to other expenditures and help in the budget planning process.
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The cost of implementing and monitoring informed consent will depend on the guidelines and
procedures established by the organizations sponsoring or conducting the research. These costs
may even vary within one research project, as implementation of the informed consent process
often happens at the local level, where guidelines can be interpreted very differently.
Frontiers, a health systems research project of the Population Council, is carrying out 61 studies
in 25 countries, all of which include informed consent. In order to strengthen oversight of the
informed consent process, project managers reviewed a sample of informed consent records and
interviewed researchers, data collectors, and study managers about their views on the costs and
benefits of the informed consent process. The review was completed in 19 of the 61 study sites.
The following points were raised about the costs of informed consent:
The cost of oversight is seen as potentially large. Research projects often have fixed-cost
budgets, which may not allow for the expense of monitoring the informed consent process.
Staff may see the informed consent process as “one more thing” to do—one of many
“burdensome” bureaucratic obligations with which they must comply.
Project staff are not always certain what they are expected to do. Guidelines can be helpful,
but they often leave uncertainty about application and implementation in a particular study
or setting.
The benefits of informed consent included:
Participants appreciate information that gives them a better understanding of the study.
Better-informed study participants are more committed to the research and are thus less
likely to leave the study.
Data quality may be improved because the participants understand the study better and are
more likely to give thoughtful responses.
Researchers and their institutions are protected from litigation.
The cost of oversight increases as activities are added to ensure that the informed consent
process is carried out properly. Some of the determinants of marginal costs include:
Complexity of the research project;
Amount of training and supervision that may be required;
Number and geographic dispersion of the study sites; and
Level of documentation required.
The “cost”—monetary or otherwise—of implementing informed consent can vary depending on
the perspective of who incurs the cost. The cost of the informed consent process for the study
participant is likely to be relatively low, although the cost of actual participation in the study may
be significantly higher. For study managers and researchers, the cost of informed consent may be
relatively high. It can be time-consuming and, especially if on a fixed-cost contract, the costs
incurred may not be adequately covered by the budget. For an institution, the cost is likely to be
modest.
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On the other hand, the cost of not implementing a comprehensive informed consent process to
study participants can be quite high: They may be uninformed about the study, may potentially
be exposed to risk without their knowledge or consent, and may not have the means to resolve
complaints. For the institution, the costs of non-compliance can also be high: Research may be
suspended or more closely scrutinized, the institution may be subject to financial and
management audits, and research funds may be withdrawn.
In order to effectively monitor informed consent, standards must be established for different
components of the process (e.g., informed consent forms, staff training, procedures to maintain
data, and guaranteeing privacy). In addition, markers or clues must be identified that can
highlight a need to initiate closer scrutiny and perhaps undertake an external review.
Any analysis of costs and benefits of the informed consent process should include some of the
less obvious benefits of informed consent, such as the increased knowledge gained by the
participants that may have significant benefits outside the study setting. It is also important to
consider the sustainability of benefits beyond the research period. For example, the informed
consent document might be adapted for use if a product or procedure is later introduced into the
service-delivery setting, thus reducing the costs of materials development at that stage.
An assessment of costs should also take into account the availability of resources and the
competing demands for their use. The poorer a country, the more burdensome the costs of
research may seem. For example, for a country like Mozambique, which spends $75 million
annually on health, a $3 million study would constitute 4 percent of its total health budget.57
While the research may provide benefits to the study participants, the costs of doing the research
are disproportionate to the resources available for health. This leads to questions about why
research is conducted in a given setting: Is it to help the people in that country or because there is
a high incidence of the condition being researched in that country, or is it simply cheaper to do
research in that country? The issues around the costs of informed consent are part of a broader
ethical debate regarding the appropriateness of conducting high-priced research in resource-poor
settings.
CONCLUSION
The field of research on drugs, devices, and procedures is rapidly growing and diversifying. The
challenge is to develop a process that includes the key actors—researchers, governments,
nongovernmental organizations, funding agencies, sponsors, and diverse communities and
constituencies—to ensure that research is conducted in a manner that is sound and ethical, with
informed consent at its core.
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As the issues around doing ethical research in health will only grow in scope and complexity, the
community of people and institutions concerned about informed consent and charged with
protecting the rights of research participants should consider the following:
As the conduct of medical research becomes increasingly globalized, it is important to look
outside of the United States for examples of how to do ethical research, including informed
consent. The laws and practices of France, Germany, India, Japan, and South Africa, for
example, differ significantly from those of the United States. As both private industry and
public research organizations in these countries increase both their investment in
developing new pharmaceutical products and their participation in clinical research, their
approaches will become more influential.
The expansion and growing complexity of the field of medical research has increased the
possibility of exploitation. Many researchers wrestle with the practical issues of
implementing research in an ethically sound manner. However, the motivations for
research are complex—among them profit, prestige, professional advancement, increased
knowledge, and improved public health—making ethical guidelines difficult to implement
and monitor. Given this, even the most comprehensive ethical guidelines or review
processes cannot completely safeguard against unethical research.
Recent developments in the pricing of AIDS drugs have increased awareness of the critical
need to ensure that the benefits of drug development are shared by the people who
participate in sometimes risky and burdensome research and the public, rather than going
disproportionately to corporate stockholders or populations in wealthy countries or
communities.
The desire to speed up the development and approval processes for some products and
procedures (e.g., AIDS drugs) needs to be tempered with the recognition that the current
system, including requirements concerning informed consent, has evolved in response to
past abuses. The imperative to protect potential research participants and future consumers
of the products remains vitally important, even in the face of urgency. Indeed, current
rigorous standards for the conduct of trials, including those for informed consent, should
only be modified with great thought, consultation, and consideration of all of the possible
implications.
This two-day seminar was an opportunity for representatives of research institutions, academic
institutions, IRBs, governments, and funding agencies to discuss informed consent—from the
philosophical foundations of ethical codes to the challenges of implementation. Sessions that
explored the history and evolution of informed consent underscored its centrality to the conduct
of ethical research. Sessions on the “nuts and bolts” of the informed consent process—
developing the forms, undergoing IRB review, finding ways to convey risk and to assess
participant comprehension—fostered discussion about practical ways to implement meaningful
informed consent. Specific examples, such as the National Cancer Institute’s initiative to involve
patients and patient advocates in an effort to refine the informed consent process, provided
promising indications of the willingness of institutions to focus resources specifically on
improving informed consent.
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Throughout the seminar, participants deliberated about the challenges and opportunities
presented in translating good intentions into sound practices, echoing Henry Beecher’s
comments that “The reality is that informed consent is often exceedingly difficult or impossible
to obtain in any complete sense. The difficulties inherent in this complex situation are no excuse
for giving up the effort: informed consent is a goal toward which we strive.”58

58

Beecher, Henry K. 1966. “Consent in clinical experimentation: Myth and reality,” Journal of the American
Medical Association 195(1):124–125.

32

Appendix 1: Meeting Agenda
Thursday, 24 May
9:15–9:30 a.m.

Welcome
Beverly Winikoff

9:30 a.m.–12:00 p.m.

Informed Consent: An Overview

Chair: Rachael Pine

Informed Consent: Lessons of the Past, a Guide
to the Future?
Ronald Bayer
International Guidelines and IRBs
Bette-Jane Crigger
Discussant
Anrudh Jain
Commentary
Rachael Pine
• Informed consent in the context of research ethics
– Key components of informed consent
• Institutional responsibility for informed consent
– Role and function of Institutional Review Boards (IRBs)
– Current international debates concerning research ethics
– Applying standards and regulations to multi-country studies
Discussion
1:00–3:15 p.m.

Informed Consent in Varying Contexts

Chair: Purnima Mane

Informed Consent: Miss or Bust?
Arthur L. Caplan
Developed vs. Developing Countries
Suniti Solomon
• Developed and developing country/cultural contexts
• Research and services
• Trials for prevention and treatment
Discussion
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3:30–5:00 p.m.

Understanding Risk and Its
Implications for Decisionmaking

Chair: Sarah Hawkes

What Is It?: Understanding and Communicating Risk
Kimberly Thompson
Explaining Risk in Biomedical Research
Elof Johansson
Flower Diagram Consent Form
Saran Da Ly
• How are risks presented?
• How is risk perceived?
• How does risk perception affect decisions?
Discussion
Friday, 25 May
9:30 a.m.–12:30 p.m.

Informed Consent:
Implementation and Evaluation

Chair: Barbara Friedland

Informed Consent: Making It Understandable—
The Recommendations of an NCI Working Group
Mary McCabe
Assessing Informed Consent
Judith A. Fortney
Evaluating the Informed Consent Process in a Phase 2
Microbicides Trial in Cape Town, South Africa
S’phindhile Magwaza
Informed Consent: What Can It Mean in Rural Gambia?
Katie Paine
• The informed consent process
– Communicating information, and developing informed consent
forms and supplementary materials
• Assessing informed consent
– What do study participants understand?
– What research methods have been used to assess their
understanding?
– How well do participants need to understand the study to make
an “informed” decision? How should this be assessed and who
should decide?
– Examples from the field
Discussion
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1:30–3:30 p.m.

Informed Consent in Special
Populations/Situations

Chair: Robert J. Levine

Special Populations
Robert J. Levine
Including Adolescents in Reproductive Health Research:
Informed Consent and Developmental Capacity
John Santelli
Consenting Male Partners of Women Involved in Reproductive
Health Research: Rights, Realities, and Responses
Ellen Weiss
Informed?? Consent?? Considerations on Carrying Out Research
in Forced Migration Settings
Therese McGinn
• What are the ethics of informed consent among legal “minors” in
the United States and elsewhere?
• What are the rights of male partners of female reproductive
health study participants if what is being studied also affects the
male partners?
• What are the ethical informed consent concerns for reproductive
health research with refugee populations and/or in emergency
situations?
Discussion
3:45–4:45 p.m.

Cost/Benefits/Burdens of Informed
Consent and Implications for Research

Chair: Shelley Clark

The Price and Value of Consent
John Townsend
International Finance and Informed Consent
Ok Pannenborg
• What are feasible/realistic/acceptable standards?
• Can informed consent be a barrier to research?
• Devising a cost/benefit analysis (or approach) to informed
consent
4:45–5:00 p.m.

Closing Comments
Beverly Winikoff
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